Page last updated: 2024-11-12

putrebactin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

putrebactin: an iron-chelating agent isolated from Shewanella putrefaciens; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16654915
CHEBI ID50432
MeSH IDM0525415

Synonyms (6)

Synonym
1,11-dihydroxy-1,6,11,16-tetraazacycloicosane-2,5,12,15-tetrone
putrebactin
CHEBI:50432
1,11-dihydroxy-1,6,11,16tetraaza-cycloicosane-2,5,12,15-tetraone
Q27122066
1,11-dihydroxy-1,6,11,16-tetrazacycloicosane-2,5,12,15-tetrone

Research Excerpts

Overview

Putrebactin is a dihydroxamate iron chelator produced by the metabolically versatile marine bacterium Shewanella putrefaciens.

ExcerptReferenceRelevance
"Putrebactin is a dihydroxamate iron chelator produced by the metabolically versatile marine bacterium Shewanella putrefaciens. "( Identification of a gene cluster that directs putrebactin biosynthesis in Shewanella species: PubC catalyzes cyclodimerization of N-hydroxy-N-succinylputrescine.
Arbache, S; Challis, GL; Kadi, N; Oves-Costales, D; Song, L, 2008
)
2.05
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cyclic hydroxamic acidA lactam having a hydroxy substituent on the amide nitrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
putrebactin biosynthesis416

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's9 (69.23)24.3611
2020's3 (23.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]